Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

Completed · Phase 1

Conditions studied: Lupus

In brief

The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.3-30 mg/kg, in adult patients with SLE and who are receiving 20 mg/day or less of prednisone orally or an equivalent dose of another oral corticosteroid.

Key facts

Study ID

NCT00299819

Run by

MedImmune LLC

People needed

45

Starts

2006-03-01

Expected to finish

2007-10-01

Last updated by the study team

2007-12-18

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must meet all of the following criteria:
• Adult males and females ≥ 18 years at the time of the first dose of study drug.
• Written informed consent obtained from the patient/patient's legal guardian
• Diagnosis of SLE: Patients must have previously met ≥ 4 of the 11 revised ACR criteria
• Current background treatments may include the following medications prior to randomization: acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), and antimalarials, such as hydroxychloroquine ≤ 600 mg/day, and prednisone ≤ 20 mg daily (or an equivalent dose of another oral corticosteroid) for at least 28 days
• Sexually active females, unless surgically sterile or at least two years post-menopausal, must use an effective method of avoiding pregnancy (including oral, injectable, transdermal, or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 28 days before the first dose of study drug, and must agree to continue using such precautions through the study period of 84 days. Cessation of birth control after this point should be discussed with a responsible physician. Sexually active males, unless surgically sterile, must likewise use an effective method of birth control (condom or abstinence) and must agree to continue using such precautions through Study Day 84.
• Ability to complete follow-up period of 84 days as required by the protocol.

You may not qualify if…

• Weight ≥ 120 kg
• Use of cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil or cyclosporine within 28 days before study entry
• Use of doses of corticosteroids higher than the equivalent of prednisone 20 mg/day (or an equivalent dose of another corticosteroid) within 28 days before study entry
• In the opinion of the investigator, a likelihood of requiring initiation of immunosuppressant therapy (e.g., prednisone >20 mg daily (or an equivalent dose of another oral corticosteroid), azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, or dapsone) within the 28 days after study entry. Antimalarial dosing must be held constant during the study, but analgesics and NSAIDs may be varied.
• Current treatment with coumadin
• Treatment with immunoglobulin or blood products within 28 days before entry into the study
• Treatment with any investigational drug therapy within 28 days before entry into the study; in the case of cell-depleting therapies, such as B or T cell depletion, cell counts that remain below acceptable or baseline levels (use of licensed agents for indications not listed in the package insert is permitted)
• History of primary immunodeficiency
• History of allergic reactions likely to be exacerbated by any component of the study drug
• Previous medical history, or evidence, of an intercurrent illness, other than SLE, that may compromise the safety of the patient in the study
• Clinically significant cardiac disease, including: unstable angina; myocardial infarction within 6 months; congestive heart failure; arrhythmia requiring active therapy, with the exception of clinically insignificant extra systoles, or minor conduction abnormalities; and history of clinically significant abnormality on electrocardiogram
• Evidence of significant active infection, or vaccination with live attenuated viruses, currently or in the 2 weeks before randomization
• Evidence of infection with hepatitis B or C virus, or HIV-1 or HIV-2, or active infection with hepatitis A, as determined by results of testing at screening
• A history of severe infection with viruses of the herpes family including Epstein-Barr virus requiring hospitalization, disseminated herpes, herpes encephalitis, ophthalmic herpes, or cytomegalovirus
• Herpes zoster ≤ 3 months prior to screening
• Current suppressive antiviral therapy for herpes or other viral infections
• Ongoing, chronic infectious disease such as chronic renal infection or chronic chest infection with bronchiectasis or sinusitis
• Pregnancy (females, unless surgically sterile or at least two years post-menopausal must have a negative serum pregnancy test within 14 days before receiving the study drug and a negative urine pregnancy test on Study Day 0 before receiving the study drug)
• Nursing mother
• History of alcohol or drug abuse within the past 2 years
• Presence of end-stage renal disease, or rapidly progressive glomerulonephritis
• Active central nervous system lupus
• History of stroke, or any cerebrovascular disease requiring medication/treatment.
• History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy >1 year prior to enrollment
• At screening (must be within14 days before entry into the study) any of the following:

Where it is running

• Pinnacle Research Group — Anniston, Alabama, United States
• Wallace Rheumatic Study Center — Los Angeles, California, United States
• Clinical Research of West Florida — Clearwater, Florida, United States
• Center for Rhematology, Immunology, and Arthritis — Fort Lauderdale, Florida, United States
• Ocala Rheumatology Research Center — Ocala, Florida, United States
• Tampa Florida Medical Research Group — Tampa, Florida, United States
• Florida Medical Clinic, Clinical Research Division — Zephyrhills, Florida, United States
• Louisiana State University Health Sciences Center-Shreveport — Shreveport, Louisiana, United States
• Johns Hopkins University, School of Medicine — Baltimore, Maryland, United States
• St. Mary's Duluth Clinic — Duluth, Minnesota, United States
• Hospital for Special Surgery — New York, New York, United States
• Columbia University Medical Center — New York, New York, United States
• Oklahoma Medical Research Foundation — Oklahoma City, Oklahoma, United States
• Oregon Medical Research Center — Portland, Oregon, United States
• Altoona Center for Clinical Research — Duncansville, Pennsylvania, United States
• University of Texas Southwestern Medical Center — Dallas, Texas, United States
• University of Washington Div. of Rhematology — Seattle, Washington, United States
• Center for Innovative Therapy, UCSD School of Medicine — Milwaukee, Wisconsin, United States
• Froedtert Hospital, Medical College of Wisconsin — Milwaukee, Wisconsin, United States
• Toronto Western Hospital — Toronto, Ontario, Canada
• Montreal General Hospital — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.